CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Series 1, Series 2 and Bridge warrant Common Stock Common stock - voting	Series 1, Series 2 and Bridge warrant Additional paid-in capital	Series 1, Series 2 and Bridge warrant	Series 3 warrants Common Stock Common stock - voting	Series 3 warrants Additional paid-in capital	Series 3 warrants	Series 1 and Series 2 warrants Common Stock Common stock - voting	Series 1 and Series 2 warrants Additional paid-in capital	Series 1 and Series 2 warrants	Series 1, Series 2, and 2019 Bridge Note warrants May 2020 Common Stock Common stock - voting	Series 1, Series 2, and 2019 Bridge Note warrants May 2020 Additional paid-in capital	Series 1, Series 2, and 2019 Bridge Note warrants May 2020	Series 1, Series 2, and 2019 Bridge Note warrants June 2020 Registered public offering Common Stock Common stock - voting	Series 1, Series 2, and 2019 Bridge Note warrants June 2020 Registered public offering Additional paid-in capital	Series 1, Series 2, and 2019 Bridge Note warrants June 2020 Registered public offering	Series 1, Series 2, and 2019 Bridge Note warrants June 2020 Common Stock Common stock - voting	Series 1, Series 2, and 2019 Bridge Note warrants June 2020 Additional paid-in capital	Series 1, Series 2, and 2019 Bridge Note warrants June 2020	Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stock Common Stock Common stock - voting	Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stock Additional paid-in capital	Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stock	PIPE Financing warrants, Dec 2019	ELOC Additional paid-in capital	ELOC	Private Investment in Public Entities Common Stock Common stock - voting	Private Investment in Public Entities Additional paid-in capital	Private Investment in Public Entities	March 2020 Equity Purchase Agreement Preferred Stock Common stock - voting Option	March 2020 Equity Purchase Agreement Preferred Stock Common stock - voting	March 2020 Equity Purchase Agreement Additional paid-in capital Option	March 2020 Equity Purchase Agreement Additional paid-in capital	March 2020 Equity Purchase Agreement Option	March 2020 Equity Purchase Agreement	Underwriter Settlement Agreement Common Stock Common stock - voting	Underwriter Settlement Agreement Additional paid-in capital	Underwriter Settlement Agreement	At The Market Offering Common Stock Common stock - voting	At The Market Offering Additional paid-in capital	At The Market Offering	Registered Direct Offering Additional paid-in capital	Registered Direct Offering	CVP Exchange Notes Common Stock Common stock - voting	CVP Exchange Notes Additional paid-in capital	CVP Exchange Notes	Preferred Stock Series A convertible preferred stock	Preferred Stock Series B convertible preferred stock	Preferred Stock Series B-2 Preferred Stock	Preferred Stock Series C perpetual preferred stock	Preferred Stock Common stock - voting	Common Stock Series B convertible preferred stock	Common Stock Series B-2 Preferred Stock	Common Stock Series C perpetual preferred stock	Common Stock Common stock - voting Atlas	Common Stock Common stock - voting PoC Capital, LLC	Common Stock Common stock - voting Pacific Capital Management LLC	Common Stock Common stock - voting	Common Stock Common stock - non-voting	Common Stock Series D perpetual preferred stock	Additional paid-in capital Series B convertible preferred stock	Additional paid-in capital Series B-2 Preferred Stock	Additional paid-in capital Series C perpetual preferred stock	Additional paid-in capital Series D perpetual preferred stock	Additional paid-in capital Atlas	Additional paid-in capital PoC Capital, LLC	Additional paid-in capital Pacific Capital Management LLC	Additional paid-in capital	Noncontrolling Interest	Accumulated deficit	Series B-2 Preferred Stock	Series D perpetual preferred stock	Atlas	PoC Capital, LLC	Pacific Capital Management LLC	Total
Beginning Balance at Dec. 31, 2019																																													$ 9,895,000
Beginning Balance (in shares) at Dec. 31, 2019																																													5,524,926
Increase (decrease) in temporary equity
Accretion to redemption value of redeemable preferred stock																																													$ 1,332,000
Ending Balance (in shares) at Dec. 31, 2020																																																																					0	0
Stockholders' Equity, beginning of period at Dec. 31, 2019																																														$ 476,000	$ 1,236,000									$ 1,000	$ 4,000									$ 142,046,000		$ (133,090,000)						$ 10,673,000
Beginning Balance (in shares) at Dec. 31, 2019																																														1,971	10,165									4,757,683	40,301,237
Increase (decrease) in Stockholders' Equity (Deficit)
Issuance of common stock																										$ 668,000	$ 668,000								$ 45,000	$ 45,000				$ 1,207,000	$ 1,207,000
Issuance of common stock (In shares)																									571,427									33,333			1,271,639
Deemed dividend attributable to Series 1 warrant modification		$ (856,000)	$ (856,000)																																													$ 2,521,000													$ (2,521,000)
Warrants issued in Underwriter settlement agreement																																			31,000	31,000
Issuance of common stock in exchange for services																														$ 10,000	$ 33,000	$ 10,000	$ 33,000																															$ 437,000								$ 437,000
Issuance of common stock in exchange for services (in shares)																												17,333	22,935																									444,444
Shares issued to Iliad in exchange of Royalty Interest																																																																		256,000								256,000
Shares issued to Iliad in exchange of Royalty Interest (in shares)																																																								438,324
Shares issued on exchange of Series perpetual preferred stock																																																$ (4,847,000)										$ 1,000			4,847,000	$ 7,876,000								$ 7,877,000
Shares issued on exchange of Series perpetual preferred stock (Shares)																																																(858,810)				2,817,959						5,296,623
Shares issued to Atlas Sciences for settlement of Trial Delay Fee																																																															$ 612,000								$ 612,000
Shares issued to Atlas Sciences for settlement of Trial Delay Fee (in shares)																																																					666,666
Shares issued on conversion of warrants of Atlas for settlement of Trial Delay Fee																																																				$ 1,000									(1,000)		$ 1,904,000		$ 24,000						$ 1,904,000		$ 24,000
Shares issued on conversion of warrants of Atlas for settlement of Trial Delay Fee (in shares)																																																				2,352,563	2,072,984		16,666
Extinguishment of Series C perpetual preferred stock																																																$ (2,521,000)													$ 2,521,000
Issuance of warrants																						$ 465,000
Modification of warrants		856,000	856,000
Shares issued on conversion of Series B-2 convertible preferred stock																																															$ (1,236,000)													$ 1,236,000
Shares issued on conversion of Series B-2 convertible preferred stock (in shares)																																															(10,165)				748,761
Accretion to redemption value of redeemable preferred stock																																																																		1,332,000								1,332,000
Underwriter settlement offering cost																																			$ (185,000)	$ (185,000)
Conversion of Series B convertible preferred stock into common stock																																														$ (476,000)													$ 476,000										$ (1,236,000)
Conversion of Series B convertible preferred stock into common stock (shares)																																														(1,971)				1,474,416
Shares issued to Sagard Capital in exchange of services																																																																		879,000								879,000
Shares issued to Sagard Capital in exchange of services (in shares)																																																								763,158
Value of shares issued on exercise of warrants		392,000	392,000		$ 6,057,000	$ 6,057,000		$ 626,000	$ 626,000		$ 3,788,000	$ 3,788,000					$ 359,000	$ 359,000		$ 2,341,000	$ 2,341,000
Shares issued on exercise of warrants	182,986			2,818,779			426,416			2,890,283						244,104			416,666
Series A convertible preferred stock redeemed and Series C perpetual preferred issued under the exchange transaction																																													$ (11,227,000)			$ 4,717,000																		150,000								4,867,000
Series A convertible preferred stock redeemed and Series C perpetual preferred issued under the exchange transaction (in shares)																																													(5,524,926)			842,500
Stock dividend attributable to Series C perpetual preferred stock of $8 per share																																																$ 130,000																		(130,000)
Stock dividend attributable to Series C perpetual preferred stock of $8 per share (in shares)																																																16,310
Shares issued to third party for services																																																																		105,000								105,000
Shares issued to third party for services (in shares)																																																								91,666
Shares issued in exchange of CVP Exchange Notes																																										$ 1,000	$ 6,512,000	$ 6,513,000
Shares issued in exchange of CVP Exchange Notes (in shares)																																										7,157,239
Conversion of non-voting common stock to voting common stock																																																									$ (4,000)									4,000
Conversion of non-voting common stock to voting common stock (Shares)																																																								12,120	(38,180,451)
Shares issued upon exercise of stock options (in shares)																																																	185
Fractional shares (in shares)																																																	62
Stock-based compensation																																																																		2,824,000								2,824,000
Net loss																																																																				(33,809,000)						(33,809,000)
Stockholders' Equity, end of period at Dec. 31, 2020																																																								$ 4,000										184,097,000		(166,899,000)						17,202,000
Ending Balance (in shares) at Dec. 31, 2020																																																								38,007,420	2,120,786
Ending Balance (in shares) at Dec. 31, 2021																																																																					0	0
Increase (decrease) in Stockholders' Equity (Deficit)
Issuance of common stock													$ 1,000	$ 23,231,000	$ 23,232,000											$ 1,751,000	$ 1,751,000											$ 8,595,000	$ 8,595,000
Issuance of common stock (In shares)													4,028,290												725,906												2,931,446
Shares issued on conversion of Napo merger common shares (in shares)				726
Shares issued to Iliad in exchange of notes payable and accrued interest																																																																		2,982,000								2,982,000
Shares issued to Iliad in exchange of notes payable and accrued interest (in shares)																																																								588,235
Issuance of warrants																							$ 124,000	$ 124,000
Shares issued in extinguishment of Exchange Note 2																																																																		2,516,000								2,516,000
Shares issued in extinguishment of Exchange Note 2 (in shares)																																																								471,202
Value of shares issued on exercise of warrants		$ 2,034,000	$ 2,034,000		$ (1,776,000)	$ (1,776,000)
Shares issued on exercise of warrants	1,383,524			206,915
Shares issued to third party for services																																																																		16,000								16,000
Shares issued to third party for services (in shares)																																																								5,666
Shares issued upon exercise of stock options																																																																		4,000								4,000
Shares issued upon exercise of stock options (in shares)																																																								3,147
Fractional shares (in shares)																																																								50
Stock-based compensation																																																																		3,974,000								3,974,000
Merger of noncontrolling interest																																																																			$ 247,000							247,000
Net loss																																																																			(5,000)	(52,595,000)						(52,600,000)
Stockholders' Equity, end of period at Dec. 31, 2021																																																								$ 5,000	$ 2,120,786									$ 231,100,000	$ 242,000	$ (219,494,000)						$ 11,853,000
Ending Balance (in shares) at Dec. 31, 2021																																																								48,352,527